CF
PTHS

Cantor Fitzgerald’s Pelthos Therapeutics PTHS Stock Holding History

Cantor Fitzgerald’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$870K Buy
41,423
+6,433
+18% +$153K 0.01% 184
2025
Q4 		$1.08M Buy
+34,990
New +$1.01M 0.02% 158

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Cantor Fitzgerald's PTHS Position: Q1 2026 in Review

Cantor Fitzgerald increased its Pelthos Therapeutics (PTHS) stake by 18% in Q1 2026, buying an estimated $153K and bringing the position to 41,423 shares worth $870K. The position accounts for 0.01% of the portfolio, ranked #184.

Cantor Fitzgerald first reported a position in PTHS in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.08M in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Cantor Fitzgerald held 41,423 shares of Pelthos Therapeutics worth $870K as of Q1 2026.
  • Cantor Fitzgerald bought 6,433 Pelthos Therapeutics shares in Q1 2026, an estimated $153K.
  • Pelthos Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #184 holding.
  • Cantor Fitzgerald first reported a position in Pelthos Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Cantor Fitzgerald's Pelthos Therapeutics position peaked at $1.08M in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.